ID: h-63ef3ee258
Hypothesis
Amyloid first impairs cholinergic terminals through alpha7 nicotinic receptor-dependent synaptotoxicity
Soluble amyloid oligomers may injure cholinergic terminals via CHRNA7-linked calcium dysregulation, making cholinergic dysfunction an early downstream readout of amyloid toxicity.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Soluble amyloid oligomers may injure cholinergic terminals via CHRNA7-linked calcium dysregulation, making cholinergic dysfunction an early downstream readout of amyloid toxicity. This remains mechanistically plausible but is not a strong lead translational thesis.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid<br/>Accumulation"]
B["Alpha7 Nicotinic<br/>Receptor Dysfunction"]
C["CHRNA7<br/>Synaptotoxicity"]
D["Cholinergic<br/>Terminal Loss"]
E["Cognitive<br/>Impairment"]
A --> B
B --> C
C --> D
D --> E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation and synaptic dysfunction.
Supports
Alpha7 nicotinic receptor agonists protect against beta-amyloid toxicity.
Supports
Alpha7 nicotinic receptors in amyloid-beta binding and tau phosphorylation.
Supports
Targeting alpha7 nicotinic receptors for Alzheimer's disease therapy.
Supports
Alpha7 nAChR agonists attenuate amyloid-beta induced cholinergic dysfunction.
Contradicts
Aβ-CHRNA7 binding and functional relevance are inconsistent across preparations and model systems, with weak human specificity for cholinergic terminals.
Contradicts
Alpha7-targeted cognition programs have had a poor clinical track record, limiting confidence in translational value.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — APP
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for APP, CHRNA7 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APP, CHRNA7.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0151
Events (7d)
1
Price History
▲7.8%💾 Resource Usage
LLM Tokens
19,162
$0.0575
Total Cost
$0.0575
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF human iPSC-derived cholinergic neurons are exposed to soluble amyloid-β oligomers (500 nM, 24-72 hours) THEN cholinergic terminal integrity (measured by VAChT puncta density and ChAT activity) will | Significant reduction in cholinergic terminal markers (VAChT puncta: 40-60% decrease; ChAT activity: 30-50% decrease) that is rescued by CHRNA7 blockade | — no observation — | pending | 0.55 |
| IF APP/PS1 transgenic mice are treated with a selective CHRNA7 positive allosteric modulator (PAM) starting at 3 months of age (pre-plaque) and continuing for 6 months THEN cholinergic terminal densit | Cholinergic terminal preservation in CHRNA7 PAM-treated APP/PS1 mice; VAChT density maintained at 85-100% of wild-type levels vs. 60-70% in vehicle-treated APP/ | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF human iPSC-derived cholinergic neurons are exposed to soluble amyloid-β oligomers (500 nM, 24-72 hours) THEN cholinergic terminal integrity (measured by VAChT puncta density and ChAT activity) will decrease by ≥40% compared to vehicle-treated controls, and this effect will be fully blocked by co-
Predicted outcome: Significant reduction in cholinergic terminal markers (VAChT puncta: 40-60% decrease; ChAT activity: 30-50% decrease) that is rescued by CHRNA7 blocka
Falsification: CHRNA7 antagonist fails to provide statistically significant protection (>20% rescue) against Aβ-induced cholinergic terminal loss; or Aβ oligomers fail to impair cholinergic terminals at all
pendingconf 45%
IF APP/PS1 transgenic mice are treated with a selective CHRNA7 positive allosteric modulator (PAM) starting at 3 months of age (pre-plaque) and continuing for 6 months THEN cholinergic terminal density in hippocampus (measured by VAChT immunoreactivity and [3H]NC-HEK binding) will be preserved at le
Predicted outcome: Cholinergic terminal preservation in CHRNA7 PAM-treated APP/PS1 mice; VAChT density maintained at 85-100% of wild-type levels vs. 60-70% in vehicle-tr
Falsification: CHRNA7 PAM treatment fails to preserve cholinergic terminals (no significant difference between treated APP/PS1 and vehicle-treated APP/PS1); or amyloid deposition occurs normally despite terminal pre
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.